Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7214364B2 · kind B2 · utility
7Cited by
14References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 3, 2003 |
| Grant date | May 8, 2007 |
| Priority date | — |
| Expiry date | Feb 1, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.